Latest Headlines

Latest Headlines

FDA turns to advisory panel for Yaz safety analysis

FDA has called in the cavalry for help reviewing the safety of Bayer's Yaz line of birth-control pills. The agency plans to convene an advisory panel in December to sift through the evidence on the

Bayer, union at odds over outsourcing promised jobs

The union representing some 500 Bayer employees in California is playing hardball with the German drugmaker. Union officials are suggesting the workers may cancel the three-year-old agreement between

Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field

The experimental prostate cancer drug Alpharadin took center stage at the big EMCC meeting in Stockholm, with researchers reporting that they had suspended a registration trial after

Xarelto tees up big new European approval

Bayer's ($BAY) new anticoagulant drug Xarelto won a crucial recommendation for European approval for the prevention of stroke in patients with atrial fibrillation. The drug was already approved to

Bayer scores encore for blood-thinner Xarelto in Europe

Bayer ($BAYN) and Johnson & Johnson's ($JNJ) Xarelto has notched another victory this month. European regulators have backed the potential blockbuster blood-thinner drug for approval to prevent

Report: Bayer could sell key Alzheimer's-detecting drug

Amid the upheaval of Bayer's planned restructuring is speculation that the German drugmaker could divest its experimental drug florbetaben, which is intended to home in on an Alzheimer's marker for

Abbott, Roche, Novartis top Big Pharmas for workers

Science magazine put Big Pharma firms Abbott Laboratories ($ABT), Novartis ($NVS), Roche, Eli Lilly ($LLY), AstraZeneca ($AZN) and Bayer on its list of the best biopharma employers. But none of the

J&J's blockbuster hopeful Xarelto bounces back with AdComm backing

The blood thinner Xarelto came through an FDA advisory committee meeting looking better than some had expected. The AdComm backed approval of the potential blockbuster for preventing stokes in

Deal-minded analysts eye Bayer, AZ for M&A

As the FDA's expert advisors debate the future of the Bayer-Johnson & Johnson ($JNJ) bloodthinner Xarelto, market-watchers are playing matchmaker. Bayer's stock went reeling after FDA blasted the

FDA review drops a bombshell on Bayer, J&J anti-clotting drug Xarelto

The FDA dropped a bombshell on the anti-clotting drug Xarelto (rivaroxaban) this morning, noting in an agency review that Bayer ($BAYN) and Johnson & Johnson ($JNJ) had offered insufficient data